Usability of an application device for nabiximols oromucosal spray in patients with upper limb impaired multiple sclerosis.

This study aimed to assess the usability of a specific EU-available application device for Sativex (US adopted name: nabiximols) cannabinoid-based oromucosal spray in patients with multiple sclerosis (MS) and spasticity-related upper limb and hand impairment in routine daily practice. MS patients with upper limb and hand impairment evaluated the usability of the device using an 18-item questionnaire. 60 patients were included. The comprehensibility of the instructions for use, practical handling and ergonomics of the device were rated as optimal (mean scores ≥8.9/10 across questions). Assisting trained nurses also rated the device as easy to use and helpful for drug administration (mean scores 10/10). The application device may assist MS patients with upper limb impairment self-administer nabiximols oromucosal spray.